Outside-in commercial research

Ambiki has a product advantage. This site is the case for the commercial motion to match it.

A self-directed body of research, completed before any internal access, that secret-shops the sale, measures the funnel, maps the competitors, and translates Ambiki's proprietary tools into buyer value. It argues for one accountable leader to turn a strong product into a repeatable path from awareness to revenue to retention.

In the spirit of Ambiki's own promise, because therapists deserve good tech, the buyer deserves a motion that shows it.

Read the full case →Explore the evidence

–

What the research found, at a glance

Five findings emerged from the outside-in work, none of them a product problem. Each number below links into the page that documents it.

2.9 vs 4.1

Ambiki's buyer-experience score against Fusion's: better product, weaker sale

5 / 134

Genuinely non-branded top-20 rankings across a 134-keyword study, despite 4,222 URLs

15 → 1

Captured Meta ads that amounted to a single repeated message to the wrong buyer

~28%

Reconstructed public demo capacity that went unused: conversion, not calendar, is the constraint

What this is

The thesis

Ambiki has a product advantage its current commercial motion is not yet consistently converting into market advantage. The missing layer is one accountable leader connecting positioning, demand, sales, onboarding, retention, and expansion into a measurable system.

The ask

Revisit the need for a senior commercial owner, and evaluate the fit through real work (a secret-shop walkthrough, a competitive pitch, a call review, a working session) rather than a conventional interview alone.

Every page here is self-contained and evidence-first. Start with the full case for the argument end to end, or use the map below to dig into any single strand of the research.

Dig deeper: the evidence base

Nine companion analyses. Each stands on its own; together they are the case.

THE ARGUMENTThe Commercial CaseThe flagship discussion document: the full argument for revisiting commercial leadership, the five findings, the 90-day plan, and three lower-risk ways to proceed.Read the case →01 · EVIDENCESecret-Shop & GTM AnalysisTwo calls, one buyer: Ambiki vs. Fusion. A better-fit, cheaper product loses the sale on positioning, pricing, proof, and process, scored on a 10-axis rubric.See the teardown →02 · DEMANDAcquisition Channels & SEOA 4,222-URL footprint and a 134-keyword study showing visibility that collapses the moment search moves from Ambiki's name toward buyer discovery.See the channel map →03 · MARKETCompetitor LandscapeAmbiki against Fusion/Ensora, TheraPlatform, ClinicNote, SPRY, SimplePractice and more: where the incumbents are winning discovery and how.See the field →04 · STORYPositioning by DisciplineProduct and distribution depth across SLP, OT, and PT, plus the uniqueness statement written for the economic buyer, not just the clinician.See the positioning →05 · MESSAGEValue-Copy Gap AnalysisWhere feature language ("save time," "all in one place") stops one level short of the practice-level business outcomes the buyer is actually purchasing.See the gap →06 · PROOFProprietary-Features BattlecardSix trademarked tools translated into buyer value (Reconsil, Tenalog, Pacing, Click Beacon, Seamless Swap, Session Chaining) plus the consolidation math.See the battlecard →07 · CAPACITYDemo Calendar AnalysisTwenty-three public snapshots reconstructing demo availability: evidence that the constraint is qualified demand and conversion, not slots on a calendar.See the availability →08 · MEASUREMENTKPI & Forecast ModelFunnel architecture, unit economics, an illustrative three-year forecast, and the operating cadence that would connect acquisition to retained revenue.See the model →

The decision this research asks Ambiki to revisit

Agree to a structured working evaluation of the commercial mandate and its fit. Not necessarily an offer or a reopened posting: a real test of whether the work is necessary and whether we work well together.

Read the full case →

Important evidence limitations

Secret-shopping evidence represents two calls, not a complete sales-team audit.
Public calendar availability does not reveal internal utilization, private meetings, cancellations, or staffing.
Search and social data are dated snapshots and should be refreshed before external circulation.
Review counts, pricing, and competitor claims should be reverified before use in a live presentation.
Forecast assumptions and target ranges are illustrative until replaced with Ambiki's internal data.

Prepared by Travis Dailey · July 12, 2026 · Discussion document for Ambiki's foundersOutside-in research · no internal access